Komori
Fuso Pharmaceutical Industries (4538) · InitiativeAdvanced

Special overdraft agreement to prepare for litigation payments

First written in FY2025. 1 of 2 entries say "Advanced", first in FY2026-H1. Latest entry: FY2026-H1.

2entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20252025: 22025
Same theme, other companies
Securing liquidity through a special overdraft to prepare for patent litigation paymentsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AdvancedAnnual report

    「As of the end of the interim accounting period, total assets increased by ¥3,703 million, or 4.5%, from the end of the previous fiscal year to ¥8,543 million, despite decreases in notes and accounts receivable, mainly due to the ¥8,744 million advance payment made in connection with the litigation. As stated in the notice concerning the judgment in the appellate proceedings in the lawsuit seeking an injunction against patent infringement and other relief announced on 27 May 2025, the Company entered into a special overdraft agreement with Sumitomo Mitsui Banking Corporation dated 2 June 2025 in light of the judgment ordering payment to TORAY INDUSTRIES,INC. of a total of ¥7,472,878,838 plus late-payment damages, thereby securing medium- to long-term funding liquidity.」

    The ¥8,744 million advance payment relating to the patent litigation was made, and the Company disclosed measures to secure funding liquidity through the special overdraft agreement entered into in light of the judgment.
  2. FY2025First statedAnnual report

    「In light of the judgment ordering payment to TORAY INDUSTRIES,INC. of a total of ¥7,472,878,838 plus late-payment damages, the Company entered into a special overdraft agreement with Sumitomo Mitsui Banking Corporation dated 2 June 2025 to secure medium- to long-term funding liquidity.」

    In light of the judgment ordering payment in the patent litigation, the Company entered into a special overdraft agreement dated 2 June 2025 to secure medium- to long-term funding liquidity.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.